K) Provisions and Contigent Liability:

Provisions are recognised when the Company has a present obligation as a result of past events, it is more
likely than not that and outflow resources will be required to settle the obligation, and the amount has been
reliably estimated. A contigent liablity is disclosed where there is a possible obligation or a present
obligation that may, but probably will not require an outflow resource.

19 There have been no significant events after the reporting date that require disclosure in these financial
statements except as given below:

"The Promoters of Chemo Pharma Laboratories Ltd. had entered into a Share Purchase Agreement on February 18,
2025 for stake-sale of their entire promoter's Shareholding toAtibhaAgriseeds Private Ltd (Acquirer) and theAcquirer is
in the process for completing the Open Offer as per SEBISAST Regulations, 2011.

As such, the erstwhile Board of directors have resigned w.e.f.April 16,2025 indicating a change in the management.

The above change can be captured in the table below along with the respective designations -

22 Other Statutory Information:

During the Current Year and Previous Year:

i. The Company do not have any Benami property, where any proceeding has been initiated or
pending against the Company for holding any Benami property.

ii. The Company do not have any transactions with companies struck off.

iii. The Company do not have any charges or satisfaction which is yet to be registered with ROC
beyond the statutory period.

iv. The Company has not traded or invested in Crypto currency or Virtual Currency.

v. The company was not required to submit quarterly statement of current assets banks / financial
institutions provided as security, as it did not have any borrowings from banks or financial
institutions.

Further, since the Company does not have any borrowings from banks or financial institutions,
the disclosures pertaining to utilisation of borrowings is not applicable in this regard.”

vi. The Company has not advanced or loaned or invested funds to any other person(s) or
entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded
in writing or otherwise) that the Intermediary shall:

(I) directly or indirectly lend or invest in other persons or entities identified in any manner
whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(II) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

vii. The Company have not received any fund from any person(s) or entity(ies), including foreign
entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that
the Company shall:

(I) directly or indirectly lend or invest in other persons or entities identified in any manner
whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(II) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

viii. The Company does not have any transactions which are not recorded in the books of accounts
that has been surrendered or disclosed as income during the year in the tax assessments under
the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the
Income TaxAct, 1961.

ix. There are no scheme of arrangements which have been filed by the Company under theAct and
which have been approved by the competent authority u/s 230 to 237 of theAct.

x. The Company has not been declared as wilful defaulter by any bank or financial institution or any
other lender.

xi. The Company has not revalued any property plant and equipment and intangible assets.

xii. There were no charges or satisfaction that were required to be registered with ROC.

xiii. The Company does not have any immovable properties and as such, it is not required to provide
the disclosures pertaining to the tiotle deeds of the immovable proprties.

The management assessed that carrying amount of cash and cash equivalents, trade receivables,
loans, investment in government securities, unsecured borrowings, trade payable and other financial
liabilities approximate theirfair values largely due to the short term maturities of these instruments.

C. Financial Risk Management

The Company has exposure to the following risks arising from financial instruments:

• Credit risk;

• Liquidity risk; and

• Market risk

Risk management framework

The board of directors has established the Risk Management Committee, which is responsible for
developing and monitoring the Company’s risk management policies. The committee reports regularly
to the board of directors on its activities.The Company’s risk management policies are established to
identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to
monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly
to reflect changes in market conditions and the Company’s activities. The Company, through its
training and management standards and procedures, aims to maintain a disciplined and constructive
control environment in which all employees understand their roles and obligations.

i. Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations
associated with its financial liabilities that are settled by delivering cash or another financial asset.
The Company’s approach to managing liquidity is to ensure as far as possible that it will have
sufficient liquidity to meet its liabilities when they are due, under both normal and stressed
condition, without incurring unacceptable losses or risking damage to the Company’s reputation.

The Company’s objective is to maintain a balance between continuity of funding and flexibility
through the use of surplus funds, bank overdrafts, bank loans, debentures and inter-corporate
loans.

The Company assessed the concentration of risk with respect to refinancing its debt and
concluded it to be low. The Company has access to a sufficient variety of sources of funding.

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The
amounts are gross and undiscounted, and include estimated interest payments and exclude the
impact of netting agreements.

ii. Market Risk

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest
rates and equity prices - will affect the Company’s income or the value of its holdings of financial
instruments. Market risk is attributable to all market risk sensitive financial instruments including
foreign currency receivables and payables and long term debt. We are exposed to market risk
primarily related to foreign exchange rate risk, interest rate risk and the market value of certain
commodities. Thus, our exposure to market risk is a function of investing and borrowing activities
and revenue generating and operating activities. The objective of market risk management is to
avoid excessive exposure in our revenues and costs.

The above disclosure has been determined to the extent such parties have been identified on the basis of information
available with the Company.

26 Previous year figures have been regrouped, re-arranged and re-classified wherever necessary to conform to
current year’s classification

As per our Report of even date attached

For Sanjay Rane & Associates LLP On behalf of Board of Directors

Chartered Accountants Chemo Pharma Laboratories Limited

Firm Reg. No. 121089W/W100878

Sd/-

CA. Abhijeet Deshmukh RUCHIT MEHTA

Partner DIRECTOR & CEO

Membership No. 129145 DIN: 08810586

UDIN: 25129145BMIWQ08395

BHAWNA RAJPUT UTSAV TRIVEDI

Place : Mumbai COMPANY SECRETARY & DIRECTOR & CFO

Date : May 29, 2025 COMPLIANCE OFFICER DIN: 10720143

ACS-72357